Literature DB >> 7679129

Expression polymerase chain reaction for the in vitro synthesis and epitope mapping of autoantigen. Application to the human thyrotropin receptor.

H B Burch1, E V Nagy, K C Kain, D E Lanar, F E Carr, L Wartofsky, K D Burman.   

Abstract

The clinical applicability of a newly described polymerase chain reaction directed protein expression system was assessed for the in vitro synthesis and partial epitope mapping of large radiolabeled human thyrotropin receptor (hTSH-R) protein segments. PCR amplification of targeted regions within the hTSH-R cDNA followed by in vitro transcription and translation permitted rapid synthesis of protein segments ranging in size from 18 to 62 kDa. Initial epitope mapping was directed at a 52 amino acid segment unique to the hTSH-R compared to otherwise homologous glycoprotein hormone receptors. Sera from Graves' disease patients known to have autoantibodies against the hTSH-R were used to immunoprecipitate two protein fragments differing only by the presence of the unique region in the larger fragment (E5) but not in the smaller fragment (E4). Dense precipitation bands were obtained using Graves' sera to immunoprecipitate E5 whereas little or no specific immunoprecipitation of E4 occurred. Normal sera gave only weak immunoprecipitation bands of E5. The technique provides significant advantages over conventional cloning methods and should have general applicability in the study of other protein targets of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679129     DOI: 10.1016/0022-1759(93)90264-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  1 in total

1.  A simpler and more cost-effective peptide biosynthetic method using the truncated GST as carrier for epitope mapping.

Authors:  Wan-Xiang Xu; Jian Wang; Hai-Ping Tang; Ling-Han Chen; Wen-Bo Lian; Jian-Min Zhan; Satish K Gupta; Chao-Neng Ji; Shao-Hua Gu; Yi Xie
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.